Meropenem serum concentrations in intensive care patients: a retrospective analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F20%3AE0108744" target="_blank" >RIV/00843989:_____/20:E0108744 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/20:A22029OR
Result on the web
<a href="https://www.prolekare.cz/casopisy/ceska-slovenska-farmacie/archiv-cisel" target="_blank" >https://www.prolekare.cz/casopisy/ceska-slovenska-farmacie/archiv-cisel</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Meropenem serum concentrations in intensive care patients: a retrospective analysis
Original language description
Objectives: To determine whether currently used meropenem dosages in our hospital provide adequate serum concentrations. Methods: Trough blood samples taken during the first meropenem concentration monitoring were included. For the evaluation of achievement of the pharmacokinetic/pharmacodynamic (PK/PD) target, MIC of the pathogens defined by the European Committee on Antimicrobial Susceptibility testing was selected. Results: Eighty three patients were enrolled. A large variability in meropenem trough serum concentrations was observed (median 34.3 mg/L, range < 1.0-146.1 Mg/L). The lowest PK/PD target for susceptible pathogens (100% T > MIC) was achieved in 100% of patients on dialysis and continuous renal replacement therapy (CRRT) and in 91% non-RRT patients. For pathogens with intermediate susceptibility, 100% T > MIC was attained in all patients on CRRT and 96% on dialysis, only 74% non-RRT patients achieved this PK/PD target. Patients on RRT were more likely to achieve the highest PK/PD target 100% T > 5 x MIC, P < 0.05. Higher proportion of patients on RRT would also require meropenem dose reduction if upper limit 100% T > 10 x MIC was chosen, P < 0.05. Conclusion: Administration of a standard meropenem dose to critically ill patients leads to a large concentration variability. Thus, a personalised dosing regimen is cricial for the achievement of adequate meropenem exposure.
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Česká a slovenská farmacie
ISSN
1210-7816
e-ISSN
1805-4439
Volume of the periodical
69
Issue of the periodical within the volume
5-6
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
7
Pages from-to
230-236
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-85101846372